July 31, 2016
Recommended Topic Related To:


"The U.S. Food and Drug Administration today approved Sovaldi (sofosbuvir) to treat chronic hepatitis C virus (HCV) infection. Sovaldi is the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the "...



Discontinued Warning IconPlease Note: This Brand Name drug is no longer available in the US.
(Generic versions may still be available.)



The highest documented dose administered is 1875 mg every 8 hours for 4 days in healthy subjects with INCIVEK alone. In that trial, the following common adverse events were reported more frequently with the 1875 mg q8h regimen compared to the 750 mg q8h regimen: nausea, headache, diarrhea, decreased appetite, dysgeusia, and vomiting.

No specific antidote is available for overdose with INCIVEK. Treatment of overdose with INCIVEK consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. In the event of an overdose, it is reasonable to employ the standard supportive measures, such as removing unabsorbed material from the gastrointestinal tract, employing clinical monitoring (including obtaining an electrocardiogram), and instituting supportive therapy if required.

It is not known whether telaprevir is dialyzable by peritoneal or hemodialysis.


Contraindications to peginterferon alfa and ribavirin also apply to INCIVEK combination treatment.

INCIVEK combination treatment is contraindicated in:

  • women who are or may become pregnant. Ribavirin may cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug treatment, the patient should be apprised of the potential hazard to a fetus [see WARNINGS AND PRECAUTIONS and Use In Specific Populations].
  • men whose female partners are pregnant.

INCIVEK is a strong inhibitor of CYP3A. INCIVEK is contraindicated when combined with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). INCIVEK is contraindicated when combined with drugs that strongly induce CYP3A and thus may lead to lower exposure and loss of efficacy of INCIVEK. Contraindicated drugs are listed below in Table 3 [also see DRUG INTERACTIONS, Table 5 and CLINICAL PHARMACOLOGY, Tables 6 and 7].

Table 3: Drugs that are Contraindicated with INCIVEK

Drug Class Drugs within Class that are Contraindicated with INCIVEK Clinical Comments
Alpha 1-adrenoreceptor antagonist Alfuzosin Potential for hypotension or cardiac arrhythmia
Anticonvulsants Carbamazepine, phenobarbital, phenytoin Potential for lower exposure and loss of efficacy of INCIVEK
Antimycobacterials Rifampin Rifampin significantly reduces telaprevir plasma concentrations.
Ergot derivatives Dihydroergotamine, ergonovine, ergotamine, methylergonovine Potential for acute ergot toxicity characterized by peripheral vasospasm or ischemia
GI motility agent Cisapride Potential for cardiac arrhythmias
Herbal products St. John's wort (Hypericum perforatum) Plasma concentrations of telaprevir can be reduced by concomitant use of the herbal preparation St. John's wort.
HMG-CoA reductase inhibitors Lovastatin, simvastatin Potential for myopathy including rhabdomyolysis
Neuroleptic Pimozide Potential for serious and/or life-threatening adverse reactions such as cardiac arrhythmias
PDE5 inhibitor Sildenafil (Revatio®) or tadalafil (Adcirca®) [for treatment of pulmonary arterial hypertension]a Potential for PDE5 inhibitor-associated adverse events, including visual abnormalities, hypotension, prolonged erection, and syncope
Sedatives/hypnotics Orally administered midazolamb, triazolam Prolonged or increased sedation or respiratory depression
aSee DRUG INTERACTIONS, Table 5 for co-administration of sildenafil and tadalafil when dosed for erectile dysfunction.
bSee DRUG INTERACTIONS, Table 5 for parenterally administered midazolam.

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 11/8/2013


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.